I'm wondering why you said Linzess might have a slight edge in efficacy? Did you compare Phase 3 trial results?
I'm being generous for the sake of the comparison. The SGYP trial had 21% responders in 3 mg versus 10% on placebo. You could look at that as a +11%. In one of the Linzess trials, 21% responded to drug versus 3% on placebo, or +18%. The other Linzess trial showed a +10% (16%-6%).
In this regard, people can look at the numbers and say it is an efficacy versus side effect trade-off. That's why I don't think SGYP is necessarily gobble up all the scripts within a few months.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.